Previous 10 | Next 10 |
The following slide deck was published by BeiGene, Ltd. in conjunction with this event. For further details see: BeiGene (BGNE) Presents At 41st Annual Healthcare Conference - Slideshow
The US FDA has expanded the approval of BeiGene's ( NASDAQ: BGNE ) Brukinsa (zanubrutinib) to include chronic lymphocytic leukemia and small lymphocytic lymphoma. The oncologic was already approved for Waldenström’s macroglobulinemia, marginal zone lymphoma, and mantle cel...
Two global Phase 3 trials in adult CLL patients demonstrated superior efficacy for BRUKINSA (zanubrutinib) in first-line and relapsed/refractory treatment settings BRUKINSA is the only BTKi to demonstrate superior PFS vs IMBRUVICA ® (ibrutinib) BeiGene (NASDAQ: BGNE...
U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) approved BeiGene's ( NASDAQ: BGNE ) Brukinsa to treat adult patients with chronic lymphocytic leukemia (CLL) and adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20...
MHRA marketing authorizations follow recent European Commission marketing authorizations BRUKINSA is the only treatment authorized for MZL in Great Britain BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Medi...
BeiGene ( NASDAQ: BGNE ) and Novartis' ( NVS ) tislelizumab's four new indications were added to the National Reimbursement Drug List (NRDL) released by China's National Healthcare Security Administration (NHSA). Tislelizumab's new indications include to treat a type...
Four new indications added for tislelizumab and all nine approved indications now included in NRDL KYPROLIS ® included for the first time XGEVA ® successfully renewed BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, toda...
Oral presentation for RATIONALE 305 showed improved survival and manageable safety profile for tislelizumab and chemotherapy in gastric or gastroesophageal junction cancer with PD-L1 expression BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, will share ...
Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentations. ...
Summary Today, we circle back on Zymeworks Inc. and update our analysis to account for recent events. A recent license agreement has left the company flush with cash as it continues to advance its lead candidate. An investment analysis follows in the paragraphs below. ...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...